18 FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns

• Published in: European journal of nuclear medicine and molecular imaging Vol. 47; no. 5; p. 1158
• Main Authors: Humbert, O, Cadour, N, Paquet, M, Schiappa, R, Poudenx, M, Chardin, D, Borchiellini, D, Benisvy, D, Ouvrier, M J, Zwarthoed, C, Schiazza, A, Ilie, M, Ghalloussi, H, Koulibaly, P M, Darcourt, J, Otto, J
• Format: Journal Article
• Language: English
• Published: Germany 01.05.2020
• Subjects: Carcinoma, Non-Small-Cell Lung - diagnostic imaging; Carcinoma, Non-Small-Cell Lung - therapy; Fluorodeoxyglucose F18; Humans; Immunotherapy; Lung Neoplasms - diagnostic imaging; Lung Neoplasms - therapy; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prospective Studies; Treatment Outcome; Response; Immunotherapy; Lung cancer; FDG PET; Monitoring

This prospective study aimed (1) to assess the non-small cell lung cancer (NSCLC) evolutive patterns to immunotherapy using FDG-PET and (2) to describe their association with clinical outcome. Fifty patients with metastatic NSCLC were included before pembrolizumab or nivolumab initiation. FDG-PET scan was performed at baseline and after 7 weeks of treatment (PET 1) and different criteria/parameters of tumor response were assessed, including PET response criteria in solid tumors (PERCIST). If a first PERCIST progressive disease (PD) without clinical worsening was observed, treatment was continued and a subsequent FDG-PET (PET 2) was performed at 3 months of treatment. Pseudo-progression (PsPD) was defined as a PERCIST response/stability on PET 2 after an initial PD. If a second PERCIST PD was assessed on PET 2, a homogeneous progression of lesions (termed immune homogeneous progressive-disease: iPD ) was distinguished from a heterogeneous evolution (termed immune dissociated-response: iDR). A durable clinical benefit (DCB) of immunotherapy was defined as treatment continuation over a 6-month period. The association between PET evolutive profiles and DCB was assessed. Using PERCIST on PET 1, 42% (21/50) of patients showed a response or stable disease, most of them (18/21) reached a DCB. In contrast, 58% (29/50) showed a PD, but more than one-third (11/29) were misclassified as they finally reached a DCB. No standard PET 1 criteria could accurately distinguished responding from non-responding patients. Treatment was continued in 19/29 of patients with a first PERCIST PD; the subsequent PET 2 demonstrated iPD , iDR and PsPD in 42% (8/19), 26% (5/19), and 32% (6/19), respectively. Whereas no patients with iPD experienced a DCB, all patients with iDR and PsPD reached a clinical benefit to immunotherapy. In patients with a first PD on PERCIST and treatment continuation, a subsequent PET identifies more than half of them with iDR and PsPD, both patterns being strongly associated with a clinical benefit of immunotherapy.